sulfadiazine has been researched along with naphthoquinones in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 11 (52.38) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Araujo, FG; Huskinson-Mark, J; Remington, JS | 1 |
| Dawkins, AT; Stahler, N; Terzian, LA | 1 |
| Howells, RE; Judge, BM | 1 |
| Winstanley, P | 1 |
| de Bertorello, MM; Ortiz, CS | 1 |
| Cardenal, C; Gatell, JM; Guelar, A; Mallolas, J; Miró, JM; Soriano, E; Zamora, L | 1 |
| Araujo, FG; Remington, JS; Slifer, T | 1 |
| Derouin, F; Pudney, M; Romand, S | 1 |
| Araujo, FG; Lin, T; Remington, JS | 1 |
| Araujo, FG; Remington, JS; Suzuki, Y | 1 |
| Gourdon, D; Katlama, C; Lapierre, D; Mouthon, B; Rousseau, F | 1 |
| Brettle, RP; Burns, SM; Flegg, PJ; Laing, RB; Leen, CL | 1 |
| Araujo, FG; Bryskier, A; Khan, AA; Remington, JS | 1 |
| Lewis, BD; López-Rebollar, LM; Penzhorn, BL; Swan, GE | 1 |
| Lakritz, J; Marsh, AE; Mullins, AL | 1 |
| Borner, K; Hahn, H; Kayser, O; Krause, K; Liesenfeld, O; Müller, RH; Schöler, N | 1 |
| Andersen, J; Bosler, EM; Chirgwin, K; Hafner, R; Jayaweera, DT; Leport, C; Luft, BJ; McAuliffe, V; Morlat, P; Rajicic, N; Remington, J; Roque, C; Vilde, JL | 1 |
| Arasteh, K; Borner, K; Bushrab, FN; Dunay, IR; Fitzner, R; Heimesaat, MM; Kurowski, M; Liesenfeld, O; Müller, RH; Stocker, H | 1 |
| Alves, CF; Vitor, RW | 1 |
| Ferreira, RA; Oliveira, AB; Ribeiro, MF; Tafuri, WL; Vitor, RW | 1 |
| de Almeida Vitor, RW; de Oliveira, AB; Ferreira, RA; Fujiwara, RT; Gazzinelli Guimarães, PH; Gualberto, SA; Miguel Del Corral, JM | 1 |
2 trial(s) available for sulfadiazine and naphthoquinones
| Article | Year |
|---|---|
Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiprotozoal Agents; Atovaquone; Clindamycin; Encephalitis; Female; Humans; Male; Naphthoquinones; Pyrimethamine; Recurrence; Risk Factors; Sulfadiazine; Survival Analysis; Time Factors; Toxoplasmosis, Cerebral | 1996 |
Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Atovaquone; Drug Therapy, Combination; Encephalitis; Female; Follow-Up Studies; Humans; Male; Naphthoquinones; Pyrimethamine; Sulfadiazine; Time Factors; Toxoplasma; Treatment Outcome | 2002 |
19 other study(ies) available for sulfadiazine and naphthoquinones
| Article | Year |
|---|---|
Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.
Topics: Adenine; Animals; Anti-Infective Agents; Atovaquone; Azithromycin; Brain; Clindamycin; Coccidiostats; Erythromycin; Fluorouracil; Mice; Mice, Inbred CBA; Naphthoquinones; Pyrimethamine; Sulfadiazine; Toxoplasma | 1991 |
The sporogonous of Plasmodium vivax in Anopheles mosquitoes as a system for evaluating the prophylactic and curative capabilities of potential antimalarial compounds.
Topics: Animals; Anopheles; Antimalarials; Chloroquine; Malaria; Naphthoquinones; Oxytetracycline; Penicillin G; Plasmodium vivax; Primaquine; Proguanil; Pyridines; Pyrimethamine; Quinacrine; Quinine; Quinolines; Sulfadiazine; Thiosemicarbazones | 1968 |
Sustained-release implants in the chemotherapy of experimental rodent malaria I. A comparison of the effects of some antimalarials in polydimethylsiloxane matrices.
Topics: Animals; Antimalarials; Chloroquine; Dimethylpolysiloxanes; Drug Implants; Malaria; Male; Mefloquine; Mice; Mice, Inbred Strains; Naphthoquinones; Piperidines; Plasmodium berghei; Primaquine; Proguanil; Pyrimethamine; Quinolines; Silicone Elastomers; Sulfadiazine; Triazines | 1981 |
Drug treatment of toxoplasmic encephalitis in acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Atovaquone; Clindamycin; Coccidiostats; Humans; Naphthoquinones; Pyrimethamine; Sulfadiazine; Toxoplasmosis, Cerebral | 1995 |
Isoxazoles. 9. Degradation kinetics of 4-(isoxazolylamino)-1,2-naphthoquinone in acidic aqueous solution.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Hydrogen-Ion Concentration; Isoxazoles; Kinetics; Naphthoquinones; Reference Standards; Reproducibility of Results; Solutions; Sulfadiazine; Temperature; Water | 1994 |
[Therapeutic alternatives for cases of cerebral toxoplasmosis in patients with AIDS: clarithromycin and atovaquone].
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Atovaquone; Clarithromycin; Clindamycin; Drug Therapy, Combination; Folic Acid; Humans; Male; Naphthoquinones; Pyrimethamine; Sulfadiazine; Toxoplasma; Toxoplasmosis, Cerebral | 1994 |
Rifabutin is active in murine models of toxoplasmosis.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Brain; Clindamycin; Drug Therapy, Combination; Female; Mice; Mice, Inbred CBA; Naphthoquinones; Pyrimethamine; Rifabutin; Sulfadiazine; Toxoplasmosis, Animal; Toxoplasmosis, Cerebral | 1994 |
In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Clarithromycin; Coccidiostats; Drug Combinations; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Kinetics; Mice; Minocycline; Naphthoquinones; Pyrimethamine; Sulfadiazine; Toxoplasma; Toxoplasmosis, Animal | 1993 |
The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Drug Synergism; Drug Therapy, Combination; Female; Mice; Naphthoquinones; Pyrimethamine; Sulfadiazine; Toxoplasmosis, Animal | 1993 |
Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antiprotozoal Agents; Atovaquone; Brain; Clindamycin; Disease Models, Animal; Drug Therapy, Combination; Encephalitis; Female; Mice; Mice, Inbred CBA; Naphthoquinones; Pyrimethamine; Rifabutin; Sulfadiazine; Toxoplasmosis, Cerebral; Treatment Outcome | 1996 |
Clinical features, outcome and survival from cerebral toxoplasmosis in Edinburgh AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Atovaquone; Autopsy; Azithromycin; Brain; CD4 Lymphocyte Count; Clindamycin; Drug Therapy, Combination; Female; Humans; Incidence; Lymphoma, AIDS-Related; Male; Middle Aged; Naphthoquinones; Pyrimethamine; Retrospective Studies; Sulfadiazine; Toxoplasmosis, Cerebral; United Kingdom | 1996 |
Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
Topics: Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Atovaquone; Clindamycin; Drug Therapy, Combination; Female; Ketolides; Macrolides; Mice; Naphthoquinones; Sulfadiazine; Toxoplasma; Toxoplasmosis, Animal | 1998 |
Screening of five drugs for efficacy against Babesia felis in experimentally infected cats.
Topics: Animals; Anti-Infective Agents; Antiprotozoal Agents; Babesiosis; Cat Diseases; Cats; Drug Combinations; Enrofloxacin; Fluoroquinolones; Hematocrit; Naphthoquinones; Parasitemia; Primaquine; Quinolones; Rifampin; Sulfadiazine; Trimethoprim | 2000 |
In vitro quantitative analysis of (3)H-uracil incorporation by Sarcocytis neurona to determine efficacy of anti-protozoal agents.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Cattle; Deer; DNA Replication; Glycine; Glyphosate; Herbicides; Male; Naphthoquinones; Nitriles; Pyrimethamine; Reproduction; Sarcocystis; Sulfadiazine; Sulfamethoxazole; Tetracycline; Triazines; Tritium; Uracil | 2001 |
Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Brain; Chromatography, High Pressure Liquid; Injections, Intravenous; Macrophages, Peritoneal; Male; Mice; Naphthoquinones; Sulfadiazine; Suspensions; Tissue Distribution; Toxoplasma; Toxoplasmosis, Animal | 2001 |
Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Female; Injections, Intravenous; Liver; Lung; Mass Spectrometry; Meninges; Mice; Mice, Inbred C57BL; Naphthoquinones; Pyrimethamine; Sulfadiazine; Survival Analysis; Toxoplasmosis, Cerebral | 2004 |
Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Coccidiostats; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Female; Genotype; Mice; Naphthoquinones; Random Allocation; Sulfadiazine; Toxoplasma; Toxoplasmosis, Animal; Treatment Outcome | 2005 |
Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine.
Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Female; Mice; Naphthoquinones; Random Allocation; Sulfadiazine; Toxoplasma; Toxoplasmosis, Animal; Treatment Outcome | 2006 |
New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains.
Topics: Animals; Antimalarials; Aporphines; Atovaquone; Cells, Cultured; Coccidiostats; Female; Fibroblasts; Foreskin; Humans; Inhibitory Concentration 50; Male; Mice; Naphthoquinones; Structure-Activity Relationship; Sulfadiazine; Toxoplasma; Toxoplasmosis, Animal | 2012 |